高凝患者显微外科血栓预防:新型抗凝方案
本研究回顾2007至2015年接受游离组织移植的高凝患者,2011年起采用新型抗凝方案(吻合前静脉推注普通肝素2000 U,随后以500 U/h输注并术后调至治疗水平,出院后全抗凝1个月),与2011年前仅皮下肝素者比较。新型组无血栓事件,对照组3例血栓(0% vs 17.6%,p=0.23),但新型组输血、血肿及血红蛋白更低更常见。结论提示预防优于治疗,但需权衡出血风险。
要点
- 高凝患者游离皮瓣术前静脉推注肝素2000 U并持续输注可降低血栓事件。
- 新型方案组术后输血率72.6%、血肿率26.7%,显著高于对照组。
- 血栓事件0% vs 17.6%无统计学差异(p=0.23),需权衡出血风险。
核心结论
- 对高凝患者,预防性肝素输注可能降低血栓事件和皮瓣丢失率,但术后出血并发症风险增加。
研究设计与样本
- 回顾性比较研究,纳入2007至2015年接受游离组织移植的23例高凝患者,共32个皮瓣。
- 2011年起11例患者接受新型抗凝方案,此前患者接受标准皮下肝素治疗作为对照。
主要发现
- 新型方案组无血栓事件,对照组3例血栓事件(0% vs 17.6%,p=0.23)。
- 血栓后无皮瓣挽救成功,所有皮瓣丢失均发生在对照组(0% vs 17.6%,p=0.23)。
- 新型方案组术后红细胞输注率72.6% vs 16.7%(p=0.007),血肿率26.7% vs 0%(p=0.04)。
- 新型方案组平均血红蛋白最低值6.9(1.0)g/dL,对照组8.9±1.8 g/dL(p=0.01)。
关键数值与推荐
- 新型方案:显微血管吻合前静脉推注普通肝素2000 U,随后以500 U/h输注,术后增至治疗水平,出院后全抗凝1个月。
- 对照组:仅术后皮下肝素。
临床怎么用
- 高凝患者游离皮瓣重建可考虑围手术期肝素抗凝预防血栓,但需密切监测出血并发症。
- 术后应警惕血肿和贫血,必要时输血支持。
局限性
- 样本量小(23例患者,32个皮瓣),血栓事件差异无统计学意义。
- 回顾性设计,对照组非同期,可能存在选择偏倚。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Hypercoagulable conditions are often considered relative contraindications to free flap reconstruction. This paper presents and critically examines a novel anticoagulation regimen developed to address this disease state. METHODS: Hypercoagulable patients who underwent free tissue transfer between 2007 and 2015 were identified. From 2011, all such patients were subjected to a novel anticoagulation protocol involving an intravenous bolus of 2000 U of unfractionated heparin prior to microvascular pedicle anastomosis, followed by a heparin infusion at 500 U/h, which was postoperatively increased to therapeutic levels. Patients were discharged on full anticoagulation for 1 month. Patients prior to 2011 received only subcutaneous heparin. Outcomes in patients receiving this novel anticoagulation protocol were compared to those of patients receiving standard therapy (postoperative subcutaneous heparin). RESULTS: Twenty-three hypercoagulable patients underwent reconstruction with 32 flaps. Eleven patients were administered the novel protocol. No thromboses were noted in the novel protocol cohort, while three thrombotic events occurred in the control cohort (0% vs. 17.6%, p = 0.23). No flaps were salvaged after thrombosis. All losses occurred in the control cohort (0% vs. 17.6%, p = 0.23). The novel protocol cohort was more likely to have postoperative red blood cell transfusions (72.6% vs. 16.7%, p = 0.007), hematomas (26.7% vs. 0%, p = 0.04), and lower mean hemoglobin nadirs [6.9 (1.0) vs. 8.9 ± 1.8 g/dL, p = 0.01]. CONCLUSION: The key approach to hypercoagulable patients is likely prevention over treatment. Patients who received prophylactic heparin infusions had clinically lower rates of thrombotic events and flap loss. However, this encouraging finding must be balanced with the increased risk for postoperative bleeding complications.
引用
- Nelson JA, Chung CU, Bauder AR, et al. Prevention of thrombosis in hypercoagulable patients undergoing microsurgery: A novel anticoagulation protocol. J Plast Reconstr Aesthet Surg. 2016. PMID: 28089863. doi:10.1016/j.bjps.2016.12.001
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。